Chapter 14 — Further Reading

Sources are sorted by how confident you should be in them, which is a habit worth carrying beyond this book. Tier 1 is material whose existence and location you can verify directly. Tier 2 is real findings described in ranges, because giving false precision from memory is a worse error than admitting imprecision. Tier 3 is what was constructed for teaching in this chapter, labeled so you never mistake a worked example for a citation.

Tier 1 — Verified canonical

PubMed (pubmed.ncbi.nlm.nih.gov) — the primary index for everything in this chapter. Two searches worth running as an exercise rather than just reading about: Rudman growth hormone men over 60 will return the 1990 New England Journal of Medicine paper and, more usefully, the enormous downstream citation trail. growth hormone healthy elderly systematic review will return the pooled analyses that came later. Read the abstracts of both generations back to back; the change in tone is the chapter in miniature.

ClinicalTrials.gov — search somatropin and filter by condition. This is the fastest way to see Rule 6 with your own eyes: the same molecule appears across growth hormone deficiency, Turner syndrome, Prader-Willi syndrome, short bowel syndrome, HIV-associated lipodystrophy, and more. Each is a separate claim with a separate evidence base. Then search for a completed, adequately powered, multi-year trial of growth hormone for anti-aging in healthy adults with functional endpoints. What you find — and do not find — is the ❌ rating's justification, rendered as a search result.

DailyMed (dailymed.nlm.nih.gov) — the US National Library of Medicine's repository of current FDA drug labeling. Search any somatropin product. The label is the single most useful primary document a non-specialist can read about an approved drug: the Indications section shows exactly which claims regulators accepted; Warnings and Precautions shows the monitored risks that §14.7 summarizes; Contraindications shows who should not receive it, and reading that list closely is one of the most informative ten minutes available on this topic. Note that dosing sections exist on the label and are not reproduced in this book by design.

FDA (fda.gov) — Drugs@FDA gives approval histories for growth hormone products, including the sequence in which indications were added. The regulatory chronology is itself an argument: it shows which claims were supported well enough to be approved, and when.

Williams Textbook of Endocrinology — the standard reference. The chapters on anterior pituitary physiology, growth hormone and IGF-1 action, growth hormone deficiency in children and adults, and acromegaly cover essentially everything in this chapter at greater depth and with full citation. If you read one thing from Tier 1 at length, make it the acromegaly chapter; it is where §14.8 comes from and it is far richer than any summary.

Endocrine Society clinical practice guidelines (endocrine.org) — freely accessible guidelines covering adult growth hormone deficiency and acromegaly. Guidelines are useful for a specific reason beyond their recommendations: they grade their own evidence, so you can see the field's own assessment of where the data is strong and where it is thin, in the field's own words.

The Nobel Prize records (nobelprize.org) — the 1977 Nobel Prize in Physiology or Medicine was awarded in part for work on the peptide hormones of the hypothalamus, the line of research that identified the hypothalamic releasing and inhibiting factors. The Nobel lectures and presentation speeches are freely available and are unusually readable primary accounts of how the accelerator and brake in §14.1 were actually found.

MedlinePlus and the NIH Genetic and Rare Diseases Information Center — plain-language, verifiable entries for acromegaly, growth hormone deficiency, and Laron syndrome. Useful as a sanity check when a claim about a rare condition sounds too clean.

Tier 2 — Attributed, specifics unverified

Everything here is a real body of work described honestly at the resolution I can vouch for. Where a number would be expected and is absent, that absence is deliberate. Verify specifics in Tier 1 before you quote any of it.

Rudman D, et al., New England Journal of Medicine, 1990 — the founding paper. Twelve men over 60, six months of growth hormone against untreated controls, with body composition as the measured outcome. Read the methods section before the discussion. The most valuable thing in the paper is the list of what was measured, because it is shorter than most people assume.

The journal's later comment on misuse of that article — the New England Journal of Medicine subsequently published a note observing that the 1990 article was being misrepresented in advertising for anti-aging products. I am confident this happened and would not quote its wording from memory. Worth finding, because a journal publicly disowning an interpretation of its own paper is rare enough to be instructive.

Systematic reviews of growth hormone in healthy elderly adults, mid-2000s — the most prominent appeared in a major internal medicine journal and pooled the randomized trials available at the time. The consistent conclusions: body composition changed; strength and functional capacity did not convincingly improve; adverse effects including edema, arthralgia, carpal tunnel syndrome, gynecomastia, and impaired glucose metabolism were more frequent in treated participants. Effect sizes exist in the original and are not reproduced here.

Long-term safety follow-up of adults treated with growth hormone as children — large European cohort efforts have followed these patients for decades. The results have been mixed and debated, and the central methodological difficulty is real and unresolved: people treated for pituitary disease in childhood differ from the general population in ways that are hard to adjust away. Anyone citing this literature as settled, in either direction, has not read it.

The IGF-1 and cancer epidemiology — a substantial observational literature associating higher circulating IGF-1 with incidence of several cancers, prostate, breast, and colorectal among the most frequently reported. Read at least one of these papers' limitations sections rather than only the abstract; the authors are generally far more careful than their citers.

Acromegaly outcome and mortality literature — cohort studies and national registries following patients over years to decades, consistently showing excess mortality relative to general populations and, critically, substantial improvement with biochemical control. This gradient is the causal backbone of §14.8.

Laron syndrome cohort reports — long-term follow-up of populations with inherited growth hormone receptor insensitivity, reporting strikingly low incidence of diabetes and cancer alongside other health issues. Small populations, extraordinary observations. Treat as a genuine and important signal and not as a general prescription.

Reduced growth hormone / IGF-1 signaling and longevity in model organisms — a large and well-replicated laboratory literature, including long-lived dwarf mouse strains and reduced insulin/IGF-1 signaling manipulations in invertebrates. Among the most reproducible longevity findings in biology. Also a body of work in organisms whose relationship to human aging is exactly the question at issue.

The prehistory: cadaver-derived growth hormone and CJD transmission — covered in Chapter 3's case study, with sources there. The two carry-forward lessons: natural does not mean safe, and long incubation periods mean short safety records prove little.

Tier 3 — Illustrative and constructed

Built for this chapter. Cite none of it as evidence.

• The GH axis diagram (§14.1) — the accelerator/brake schematic, drawn to make the somatostatin point visible. Simplified; ghrelin and the GH secretagogue receptor are deliberately omitted and arrive in Chapter 15.
• The deficiency-versus-aging comparison table (§14.4) — assembled to state the anti-aging argument at its strongest before dismantling the inference. Not a published table.
• FIGURE 14.1, "Twelve men, six months, and thirty-five years of consequences" (§14.5) — a reading of a real published trial in this book's six-field format. The study is real; the framing, the scope analysis, and the verdict are this book's.
• FIGURE 14.2, "How to read a natural experiment" (§14.8) — explicitly a constructed teaching composite of the acromegaly outcome literature. No single trial is being cited and no numbers are given, because none should be invented.
• The "clinic email" (§14.6) — a composite of marketing language of a common type, assembled for phrase-by-phrase analysis. Not a quotation from any real clinic, and no real person or company is described.
• The six-step account of how twelve men became an industry (§14.6) — this book's reconstruction of a reasoning cascade, not a documented history of any particular organization.
• The Field 9 dossier template and both worked growth hormone entries (§14.9 dossier) — pedagogical instruments, built for this book.
• The Laron/acromegaly two-column comparison (Case Study 14.2) — a constructed teaching summary of two real bodies of literature placed side by side for contrast.

If you only do one thing

Open DailyMed, pull up the current label for any somatropin product, and read the Indications section and the Warnings and Precautions section end to end.

Fifteen minutes, free, and it does something no summary can. The Indications list shows you exactly which claims cleared a regulatory bar and which did not — and you will notice immediately that "anti-aging" is not among them, not because anyone banned the words but because no one submitted the evidence. The Warnings section shows you the monitored risks in the language of the people legally responsible for stating them, which is a very different register from either a marketing page or a skeptic's blog.

Then read a clinic's marketing page for the same molecule. Put them side by side. Whatever else this chapter did or did not teach you, that comparison will finish the job.